Importance of the cytochrome P450 2D6 genotype for the drug metabolic interaction between chlorpromazine and haloperidol

• Published in: Therapeutic drug monitoring Vol. 23; no. 4; p. 363
• Main Authors: Suzuki, Y, Someya, T, Shimoda, K, Hirokane, G, Morita, S, Yokono, A, Inoue, Y, Takahashi, S
• Format: Journal Article
• Language: English
• Published: United States 01.08.2001
• Subjects: Adult; Aged; Antipsychotic Agents - pharmacokinetics; Antipsychotic Agents - therapeutic use; Chlorpromazine - therapeutic use; Cytochrome P-450 CYP2D6 - genetics; Drug Interactions; Drug Therapy, Combination; Genotype; Haloperidol - pharmacokinetics; Haloperidol - therapeutic use; Humans; Middle Aged; Schizophrenia - drug therapy; Schizophrenia - enzymology; Schizophrenia - metabolism
• ISSN: 0163-4356
• DOI: 10.1097/00007691-200108000-00007

The authors studied the interactive effects of the coadministration of haloperidol and chlorpromazine on plasma concentrations of haloperidol and reduced haloperidol. The subjects were 43 Japanese male schizophrenic inpatients who were concomitantly treated with chlorpromazine before or after monotherapy with haloperidol. Coadministration of chlorpromazine produced significant increases in the plasma concentrations of haloperidol (P < 0.01) and reduced haloperidol (P < 0.001) by an average of 28.5% +/- 83.3% and 160.8% +/- 288.9%, respectively. However, there were marked interindividual variations in the interactive effects of chlorpromazine. The authors analyzed the importance of five CYP2D6 genotypes, *1/ *1, *1/ *10, *10/ *10, *1/*5, and *5/*10 on the percentage of change in plasma concentrations of haloperidol and reduced haloperidol. Patients with the CYP2D6*5 allele (n = 4) showed a significantly smaller increase in plasma concentrations of haloperidol (P < 0.05) and a slightly smaller increase in those of reduced haloperidol (P = 0.074) in response to the coadministration of chlorpromazine compared than those with the CYP2D6*1/*1 genotype (n = 8). Those with the CYP2D6*1/*1 genotype (n = 8) showed a trend toward greater increases in plasma concentrations of haloperidol than those with other genotypes (P = 0.087).